Related references
Note: Only part of the references are listed.The Glucagonostatic and Insulinotropic Effects of Glucagon-Like Peptide 1 Contribute Equally to Its Glucose-Lowering Action
Kristine J. Hare et al.
DIABETES (2010)
Further Improvement in Postprandial Glucose Control With Addition of Exenatide or Sitagliptin to Combination Therapy With Insulin Glargine and Metformin A proof-of-concept study
Sabine Arnolds et al.
DIABETES CARE (2010)
Switching to Once-Daily Liraglutide From Twice-Daily Exenatide Further Improves Glycemic Control in Patients With Type 2 Diabetes Using Oral Agents
John B. Buse et al.
DIABETES CARE (2010)
An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials
M. Ligueros-Saylan et al.
DIABETES OBESITY & METABOLISM (2010)
Exenatide Versus Glibenclamide in Patients with Diabetes
G. Derosa et al.
DIABETES TECHNOLOGY & THERAPEUTICS (2010)
Metabolism and Excretion of the Once-Daily Human Glucagon-Like Peptide-1 Analog Liraglutide in Healthy Male Subjects and Its In Vitro Degradation by Dipeptidyl Peptidase IV and Neutral Endopeptidase
Monika Malm-Erjefalt et al.
DRUG METABOLISM AND DISPOSITION (2010)
Glucagon-Like Peptide-1 Receptor Agonists Activate Rodent Thyroid C-Cells Causing Calcitonin Release and C-Cell Proliferation
Lotte Bjerre Knudsen et al.
ENDOCRINOLOGY (2010)
Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial
Richard M. Bergenstal et al.
LANCET (2010)
Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial
Richard E. Pratley et al.
LANCET (2010)
Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes
Debora Williams-Herman et al.
BMC ENDOCRINE DISORDERS (2010)
Unraveling the Science of Incretin Biology
Michael A. Nauck
AMERICAN JOURNAL OF MEDICINE (2009)
Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide
Lisbeth V. Jacobsen et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide
David D. Dore et al.
CURRENT MEDICAL RESEARCH AND OPINION (2009)
From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus
Ralph A. DeFronzo
DIABETES (2009)
Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes The LEAD (Liraglutide Effect and Action in Diabetes)-2 study
Michael Nauck et al.
DIABETES CARE (2009)
Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)
Bernard Zinman et al.
DIABETES CARE (2009)
Treatment With the Human Once-Weekly Glucagon-Like Peptide-1 Analog Taspoglutide in Combination With Metformin Improves Glycemic Control and Lowers Body Weight in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Alone A double-blind placebo-controlled study
Michael A. Nauck et al.
DIABETES CARE (2009)
The Efficacy and Safety of Saxagliptin When Added to Metformin Therapy in Patients With Inadequately Controlled Type 2 Diabetes With Metformin Alone
Ralph A. DeFronzo et al.
DIABETES CARE (2009)
One-year Treatment With Exenatide Improves β-Cell Function, Compared With Insulin Glargine, in Metformin-Treated Type 2 Diabetic Patients A randomized, controlled trial
Mathijs C. Bunck et al.
DIABETES CARE (2009)
Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy
E. Ferrannini et al.
DIABETES OBESITY & METABOLISM (2009)
Long-term glycaemic effects of pioglitazone compared with placebo as add-on treatment to metformin or sulphonylurea monotherapy in PROactive (PROactive 18)
A. J. Scheen et al.
DIABETIC MEDICINE (2009)
Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
M. Marre et al.
DIABETIC MEDICINE (2009)
Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial
D. Russell-Jones et al.
DIABETOLOGIA (2009)
STATEMENT BY AN AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY CONSENSUS PANEL ON TYPE 2 DIABETES MELLITUS: AN ALGORITHM FOR GLYCEMIC CONTROL
Helena W. Rodbard et al.
ENDOCRINE PRACTICE (2009)
Repaglinide in combination therapy with metformin in Type 2 diabetes
R. Moses
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES (2009)
A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules
Hongbin Liu et al.
JOURNAL OF ENDOCRINOLOGY (2009)
Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial
Alan Garber et al.
LANCET (2009)
Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
John B. Buse et al.
LANCET (2009)
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial
Philip D. Home et al.
LANCET (2009)
Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes
David M. Nathan et al.
DIABETES CARE (2009)
Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database
Ioanna Tzoulaki et al.
BMJ-BRITISH MEDICAL JOURNAL (2009)
Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin - Glucose and lipid effects
Harold E. Bays et al.
ARCHIVES OF INTERNAL MEDICINE (2008)
Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes
Itamar Raz et al.
CURRENT MEDICAL RESEARCH AND OPINION (2008)
Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality? A meta-analysis of observational studies
Ajay D. Rao et al.
DIABETES CARE (2008)
Rosiglitazone no longer recommended
[Anonymous]
LANCET (2008)
Rosiglitazone-associated fractures in type 2 diabetes - An analysis from a diabetes outcome progression trial (ADOPT)
Steven E. Kahn et al.
DIABETES CARE (2008)
Glycaemic control and adverse events in patients with type 2 diabetes treated with metformin plus sulphonylurea: a meta-analysis
J. Belsey et al.
DIABETES OBESITY & METABOLISM (2008)
Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes
R. Scott et al.
DIABETES OBESITY & METABOLISM (2008)
Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes
J. -P. Courreges et al.
DIABETIC MEDICINE (2008)
Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus
T. Vilsboll et al.
DIABETIC MEDICINE (2008)
Regulation of Islet Hormone Release and Gastric Emptying by Endogenous Glucagon-Like Peptide 1 after Glucose Ingestion
Marzieh Salehi et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Effects of intensive glucose lowering in type 2 diabetes
Hertzel C. Gerstein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
10-year follow-up of intensive glucose control in type 2 diabetes
Rury R. Holman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
INCREASED RISK OF ACUTE PANCREATITIS OBSERVED IN PATIENTS WITH TYPE 2 DIABETES
R. A. Noel et al.
PANCREAS (2008)
Novel combination treatment of type 2 diabetes DPP-4 inhibition
Bo Ahren
VASCULAR HEALTH AND RISK MANAGEMENT (2008)
Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years
David C. Klonoff et al.
CURRENT MEDICAL RESEARCH AND OPINION (2008)
Comparison of fixed-dose rosiglitazone/metformin combination therapy with sulphonylurea plus metformin in overweight individuals with type 2 diabetes inadequately controlled on metformin alone
A. Hamann et al.
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES (2008)
Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: A multinational, randomized, open-label, two-period, crossover noninferiority trial
Anthony H. Barnett et al.
CLINICAL THERAPEUTICS (2007)
Improved meal-related insulin processing contributes to the enhancement of B-Cell function by the DPP-4 inhibitor vildagliptin in patients with type 2 diabetes
B. Ahren et al.
HORMONE AND METABOLIC RESEARCH (2007)
Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia
Mark A. Deeg et al.
DIABETES CARE (2007)
Systematic review: Comparative effectiveness and safety of oral medications for type 2 diabetes Mellitus
Shari Bolen et al.
ANNALS OF INTERNAL MEDICINE (2007)
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin
K. Hermansen et al.
DIABETES OBESITY & METABOLISM (2007)
Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes
Valeriya Lyssenko et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Rosiglitazone evaluated for cardiovascular outcomes - An interim analysis
Philip D. Home et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Nateglinide or gliclazide in combination with metformin for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone: 1-year trial results
S. Ristic et al.
DIABETES OBESITY & METABOLISM (2007)
Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes
Steven E. Nissen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Dipeptidyl peptidase-4 inhibitors -: Clinical data and clinical implications
Bo Ahren
DIABETES CARE (2007)
Initial monotherapy with either metformin or sulphonylureas often fails to achieve or maintain current glycaemic goals in patients with Type 2 diabetes in UK primary care
M. N. Cook et al.
DIABETIC MEDICINE (2007)
A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study
M. A. Nauck et al.
DIABETOLOGIA (2007)
A systematic review and meta-analysis of hypoglycemia and cardiovascular event - A comparison of glyburide with other secretagogues and with insulin
Azim S. Gangji et al.
DIABETES CARE (2007)
Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin
Emanuele Bosi et al.
DIABETES CARE (2007)
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial
M. A. Nauck et al.
DIABETES OBESITY & METABOLISM (2007)
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Steven E. Kahn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes
Pablo Aschner et al.
DIABETES CARE (2006)
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone
Bernard Charbonnel et al.
DIABETES CARE (2006)
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
Daniel J. Drucker et al.
LANCET (2006)
Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes
L. Blonde et al.
DIABETES OBESITY & METABOLISM (2006)
Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin
JMM Evans et al.
DIABETOLOGIA (2006)
Treatment escalation and rise ion HbA1c following successful initial metformin therapy
GA Nichols et al.
DIABETES CARE (2006)
Metformin revisited: re-evaluation of its properties and role in the pharmacopoeia of modern antidiabetic agents
MO Goodarzi et al.
DIABETES OBESITY & METABOLISM (2005)
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):: a randomised controlled trial
JA Dormandy et al.
LANCET (2005)
Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes
B Charbonnel et al.
DIABETOLOGIA (2005)
The long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits β-cell apoptosis in vitro
S Bregenbolt et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2005)
Inhibition of dipeptidyl peptidase IV activity by oral metformin in Type 2 diabetes
JR Lindsay et al.
DIABETIC MEDICINE (2005)
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea
DM Kendall et al.
DIABETES CARE (2005)
Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes
RA DeFronzo et al.
DIABETES CARE (2005)
Glycemic control continues to deteriorate after sulfonylureas are added to metformin among patients with type 2 diabetes
MN Cook et al.
DIABETES CARE (2005)
Exenatide (Exendin-4) improves insulin sensitivity and β-cell mass in insulin-resistant obese fa/fa Zucker rats independent of glycemia and body weight
BR Gedulin et al.
ENDOCRINOLOGY (2005)
Glitazones differentially regulate primary astrocyte and glioma cell survival -: Involvement of reactive oxygen species and peroxisome proliferator-activated receptor-γ
JM Pérez-Ortiz et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Metformin causes reduction of food intake and body weight gain and improvement of glucose intolerance in combination with dipeptidyl peptidase IV inhibitor in Zucker fa/fa rats
N Yasuda et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2004)
Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans
JJ Holst et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2004)
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes
JB Buse et al.
DIABETES CARE (2004)
Thiazolidinedione use, fluid retention, and congestive heart failure
RW Nesto et al.
DIABETES CARE (2004)
Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets
L Farilla et al.
ENDOCRINOLOGY (2003)
Enhancing incretin action for the treatment of type 2 diabetes
DJ Drucker
DIABETES CARE (2003)
Metformin and thiazolidinedione use in medicare patients with heart failure
FA Masoudi et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2003)
Efficacy and safety of combination therapy - Repaglinide plus metformin versus nateglinide plus metformin
P Raskin et al.
DIABETES CARE (2003)
Dipeptidyl peptidase IV inhibitor treatment stimulates β-cell survival and islet neogenesis in streptozotocin-induced diabetic rats
JA Pospisilik et al.
DIABETES (2003)
Acarbose improves glycemic control in overweigh type 2 diabetic patients insufficiently treated with metformin
P Phillips et al.
DIABETES CARE (2003)
The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases β-cell mass in diabetic mice
B Rolin et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2002)
Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes melitus: A randomized, placebo-controlled study
D Einhorn et al.
CLINICAL THERAPEUTICS (2000)
Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration
LB Knudsen et al.
JOURNAL OF MEDICINAL CHEMISTRY (2000)
Efficacy and safety of acarbose add-on therapy in the treatment of overweight patients with Type 2 diabetes inadequately controlled with metformin: a double-blind, placebo-controlled study
S Halimi et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2000)
Share Paper
